UBS increases its holdings of Luye Pharma (02186) by 13.95 million shares at a price of approximately HKD 2.85 per share.
On April 2nd, UBS increased its holdings in Green Leaf Pharmaceuticals (02186) by 13.95 million shares, at a price of 2.8547 Hong Kong dollars per share, totaling approximately 39.8359 million Hong Kong dollars.
According to the latest information from the Hong Kong Stock Exchange, on April 2nd, UBS increased its holdings of Luye Pharma (02186) by 13,954,500 shares, at a price of HK$2.8547 per share, for a total amount of approximately HK$39,835,900. After the increase, the latest number of shares held is approximately 403 million shares, with a new holding percentage of 10.09%.
Additional information: 218,500,000 of the reported long and short positions refer to the securities lending agreement executed in conjunction with the convertible bond issuance as disclosed on June 28, 2023.
Related Articles
Fundraising Doubles! AI chip new darling Cerebras (CBRS.US) increases IPO scale to $4 billion, fastest roadshow starting next week.
Seize the "embodied intelligence" high ground! Meta (META.US) acquires ARI to boost its humanoid Siasun Robot & Automation layout, engaging in a head-to-head competition with Tesla, Inc. and Alphabet Inc. Class C.
Nickel smelting costs have double "boosted", CICC optimistic about short-term nickel prices and revaluation of nickel and cobalt companies.
Fundraising Doubles! AI chip new darling Cerebras (CBRS.US) increases IPO scale to $4 billion, fastest roadshow starting next week.
Seize the "embodied intelligence" high ground! Meta (META.US) acquires ARI to boost its humanoid Siasun Robot & Automation layout, engaging in a head-to-head competition with Tesla, Inc. and Alphabet Inc. Class C.
Nickel smelting costs have double "boosted", CICC optimistic about short-term nickel prices and revaluation of nickel and cobalt companies.
